Ascendis Pharma gains full rights to TransCon tech, launches $400M buyback, and posts positive trial data.

Ascendis Pharma A/S regained full control of its TransCon technology for metabolic diseases from Novo Nordisk, allowing it to independently develop and sell treatments, including for obesity. The company also authorized a $400 million share repurchase program, signaling confidence in its future. Additionally, positive clinical trial results for its TransCon CNP treatment showed benefits in treating achondroplasia in infants, supporting growth prospects. Raymond James set a $287 price target, indicating potential stock appreciation despite a rating downgrade to "Outperform."

Ascendis Pharma A/S (ASND) trades at USD 236.48 on Pluang as of Sep 15, 2026 20:55 WIB, down 10.74% in one day. The stock's market cap stands at $17.43 billion, below its 52-week high of $277.18. These figures show current investor sentiment despite the company's strategic moves and positive clinical data.